• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

ST 段抬高型心肌梗死患者无复流的预测因素。

Predictor of No-Reflow in Patients With ST-Segment Elevation Myocardial Infarction.

机构信息

Department of Cardiology, University of Gazi, Ankara, Turkey.

出版信息

Angiology. 2024 Aug;75(7):696-697. doi: 10.1177/00033197231205122. Epub 2023 Sep 28.

DOI:10.1177/00033197231205122
PMID:37768690
Abstract

We have carefully read the article titled 'Prognostic Nutritional Index as a Predictor of No-Reflow Occurrence in Patients With ST-Segment Elevation Myocardial Infarction Who Underwent Primary Percutaneous Coronary Intervention' and find it to be of significant interest. The no-reflow phenomenon (NRP) stands as a formidable complication of ST-segment elevation myocardial infarction (STEMI), carrying a high mortality risk. Managing NRP entails pharmacological and mechanical interventions, making its prediction a crucial aspect in the management of STEMI cases. We extend our gratitude to you and the authors for conducting this valuable and thought-provoking study. We anticipate that our insights will serve as a guide for future comprehensive studies in this dynamic area.

摘要

我们仔细阅读了题为“Prognostic Nutritional Index 作为接受直接经皮冠状动脉介入治疗的 ST 段抬高型心肌梗死患者无复流发生的预测因子”的文章,发现它非常有趣。无复流现象(NRP)是 ST 段抬高型心肌梗死(STEMI)的一种严重并发症,具有很高的死亡率风险。管理 NRP 需要药物和机械干预,因此预测 NRP 是 STEMI 病例管理的一个关键方面。我们感谢您和作者进行了这项有价值且发人深省的研究。我们预计,我们的见解将为这一充满活力的领域的未来综合研究提供指导。

相似文献

1
Predictor of No-Reflow in Patients With ST-Segment Elevation Myocardial Infarction.ST 段抬高型心肌梗死患者无复流的预测因素。
Angiology. 2024 Aug;75(7):696-697. doi: 10.1177/00033197231205122. Epub 2023 Sep 28.
2
New CHADS-VASc-HSF score predicts the no-reflow phenomenon after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction.新型 CHADS-VASc-HSF 评分预测 ST 段抬高型心肌梗死患者行直接经皮冠状动脉介入治疗后无复流现象。
BMC Cardiovasc Disord. 2020 Jul 25;20(1):346. doi: 10.1186/s12872-020-01623-w.
3
Serum Endocan Levels Predict Angiographic No-Reflow Phenomenon in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Coronary Intervention.血清内皮细胞蛋白水平预测行直接经皮冠状动脉介入治疗的 ST 段抬高型心肌梗死患者的血管造影无复流现象。
Angiology. 2021 Mar;72(3):221-227. doi: 10.1177/0003319720961954. Epub 2020 Sep 30.
4
The relationship between atherogenic index of plasma and no-reflow in patients with acute ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention.急性 ST 段抬高型心肌梗死患者行直接经皮冠状动脉介入治疗后,血浆致动脉粥样硬化指数与无复流的关系。
Int J Cardiovasc Imaging. 2020 May;36(5):789-796. doi: 10.1007/s10554-019-01766-8. Epub 2020 Jan 9.
5
Prognostic Nutritional Index as a Predictor of No-Reflow Occurrence in Patients With ST-Segment Elevation Myocardial Infarction Who Underwent Primary Percutaneous Coronary Intervention.预后营养指数作为接受直接经皮冠状动脉介入治疗的ST段抬高型心肌梗死患者无复流发生的预测指标
Angiology. 2024 Aug;75(7):689-695. doi: 10.1177/00033197231193223. Epub 2023 Aug 8.
6
Comparison of syntax score and syntax score II to predict "no reflow phenomenon" in patients with ST-segment elevation myocardial infarction.比较Syntax评分和Syntax评分II预测ST段抬高型心肌梗死患者“无复流现象”的情况。
Int J Cardiovasc Imaging. 2017 Dec;33(12):1883-1889. doi: 10.1007/s10554-017-1200-5. Epub 2017 Jun 29.
7
CHA2DS2-VASc Score is a Predictor of No-Reflow in Patients With ST-Segment Elevation Myocardial Infarction Who Underwent Primary Percutaneous Intervention.CHA2DS2-VASc评分是接受直接经皮冠状动脉介入治疗的ST段抬高型心肌梗死患者无复流现象的预测指标。
Angiology. 2016 Oct;67(9):840-5. doi: 10.1177/0003319715622844. Epub 2015 Dec 17.
8
Impact of platelet inhibition level on subsequent no-reflow in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.血小板抑制水平对 ST 段抬高型心肌梗死患者行直接经皮冠状动脉介入治疗后无复流的影响。
Arch Cardiovasc Dis. 2017 Nov;110(11):626-633. doi: 10.1016/j.acvd.2016.12.017. Epub 2017 Jun 2.
9
Effect of GP IIb/IIIa inhibitor duration on the clinical prognosis of primary percutaneous coronary intervention in ST-segment elevation myocardial infarction with no-/slow-reflow phenomenon.无复流/慢复流现象的 ST 段抬高型心肌梗死患者行直接经皮冠状动脉介入治疗中 GP IIb/IIIa 抑制剂时间对临床预后的影响。
Biomed Pharmacother. 2021 Nov;143:112196. doi: 10.1016/j.biopha.2021.112196. Epub 2021 Sep 21.
10
In-Hospital Peak Glycemia in Predicting No-Reflow Phenomenon in Diabetic Patients with STEMI Treated with Primary Percutaneous Coronary Intervention.在接受直接经皮冠状动脉介入治疗的糖尿病合并 ST 段抬高型心肌梗死患者中,院内血糖峰值对无复流现象的预测作用。
J Diabetes Res. 2021 Jan 8;2021:6683937. doi: 10.1155/2021/6683937. eCollection 2021.

引用本文的文献

1
Myocardial contrast echocardiography predicts major adverse cardiovascular and cerebrovascular events in the population after percutaneous coronary intervention-a systematic review and meta-analysis.心肌对比超声心动图可预测经皮冠状动脉介入治疗后人群的主要不良心血管和脑血管事件——一项系统评价和荟萃分析
Cardiovasc Diagn Ther. 2025 Aug 30;15(4):802-819. doi: 10.21037/cdt-2024-664. Epub 2025 Aug 27.